Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Released May 5, 2017, after the close
10-Q filed May 5, 2017, 35 days after period end · 0001144204-17-024823
Q1 2017 · 10-Q
Revenue—
Net Income-$2.42M-$2.42MN/M vs Q1 2016N/M vs Q4 2016 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
EPS Diluted
-$0.29-$0.29N/M vs Q1 2016no prior Q4 2016 on file Operating Income-$2,416,885N/M Operating Cash Flow-$1,923,678N/M Filing lag
ended Mar 31, 2017 · filed May 5, 2017 · 35 d after period end